Chengzhi Zhang, Ph.D., is the Chief Chemist at Design Therapeutics. Dr. Zhang has more than thirty years of drug discovery and drug development experience in both big pharma and biopharmaceuticals, in roles of increasing responsibility. Prior to joining Design, Dr. Zhang was Executive Vice President at Hinova Pharmaceuticals where he oversaw CMC and medicinal chemistry departments. Before that, Dr. Zhang was Director of Chemistry and Manufacturing at Auspex Pharmaceuticals, a biopharmaceutical company focused on movement disorders. Dr. Zhang played an important role in the discovery, manufacturing to support clinical development and regulatory submission, and U.S. commercial launch of AUSTEDO® (deutetrabenazine) (both before and after Auspex’s acquisition by Teva). Dr. Zhang is a co-inventor of AUSTEDO®. Prior to that, Dr. Zhang worked at Bayer HealthCare and Novartis (GNF) as Project Leader and Medicinal Chemist, respectively, where he made major contributions to bring multiple projects from lead discovery to clinical development. Before that, Dr. Zhang worked at Ontogen Corporation and Idun Pharmaceuticals. Dr. Zhang obtained his Ph.D. in organic chemistry from the University of Alberta. He completed his post-doctoral fellowship in organic chemistry at Columbia University as an NSERC (Natural Sciences and Engineering Research Council of Canada) postdoctoral fellow.